USCAP 2024 - SOPHiA GENETICS

[et_pb_section fb_built="1" _builder_version="4.24.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.24.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.24.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.24.2" _module_preset="default" hover_enabled="0" global_colors_info="{}" theme_builder_area="post_content" custom_padding="||0px|||" sticky_enabled="0"]

SOPHiA GENETICS™ is excited to be a part of the 113th United States and Canadian Academy of Pathology annual meeting, held in person in Baltimore, Maryland from March 23rd – 28th .

Stop by booth # 1153 for a chance to meet our experts, get a sneak peak into the capabilities of the SOPHiA SOPHiA DDM™ Platform and to discover the breadth of our solid tumor and liquid biopsy capabilities.

Want to learn about our collaboration with Memorial Sloan Kettering Cancer Center (MSK) to empower laboratories worldwide with access to MSK’s advanced precision oncology tools – MSK-ACCESS® and MSK-IMPACT® – via the SOPHiA DDMTM Platform?

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Event Dates

Event Type

In-person

Event Location

North America

Areas of Interest

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expresseda during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services